A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma

A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma

BackgroundCompared with the standard of care with sunitinib, avelumab plus axitinib can increase progression-free survival in the first-line of advanced renal cell carcinoma (RCC), but the economic effect of the treatment is unknown. The purpose of the research was to evaluate the cost-effectiveness...

Full description

Bibliographic Details
Main Authors: Peiyao Lu, Weiting Liang, Jiahao Li, Yanming Hong, Zhuojia Chen, Tao Liu, Pei Dong, Hongbing Huang, Tiantian Zhang, Jie Jiang
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Pharmacology
Subjects:
cost-effectiveness
avelumab
axitinib
renal cell carcinoma
programmed death receptor
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.00619/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.00619/full

Similar Items